Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jul 22;12(1):445.
doi: 10.1186/s13104-019-4454-2.

Tenofovir-associated renal toxicity in a cohort of HIV infected patients in Ghana

Edmund T Nartey  1 , Raymond A Tetteh  2   3 , Barbara A Yankey  4 , Aukje K Mantel-Teeuwisse  2 , Hubert G M Leufkens  2 , Alexander N O Dodoo  5 , Margaret Lartey  6
Affiliations

Tenofovir-associated renal toxicity in a cohort of HIV infected patients in Ghana

Edmund T Nartey et al. BMC Res Notes. .

Abstract

Objective: Tenofovir disoproxil fumarate (TDF) is a nucleotide analogue recommended in international HIV treatment guidelines. Purpose of this study was to estimate the long term effects of TDF on renal profile in a cohort of HIV patients in Ghana. Three hundred (300) consecutive HIV-positive patients who initiated TDF-based antiretroviral treatment in 2008 at the Korle-Bu Teaching Hospital were sampled. Creatinine clearance (CrCl) was calculated using the Cockcroft-Gault equation at baseline and renal impairment was defined as CrCl values of 30.0-49.9 mL/min (moderate renal impairment) and < 30 mL/min (severe renal impairment) as per institutional guidelines for renal function test.

Results: Median follow up time was 2.9 years (IQR 2.3-3.4 years). At study endpoint, 63 participants (21.0% [95% CI 6.5-26.1]) recorded CrCl rate below 50 mL/min indicating incident renal impairment, made up of 18.3% moderate renal impairment and 2.3% severe renal impairment. Factors associated with incidence of renal impairment were increasing age, decrease in creatinine clearance rate at baseline, WHO HIV stage III/IV and participants with BMI of < 18.5 kg/m2. Patients with identified renal impairment risk factors at ART initiation should be targeted and monitored effectively to prevent renal injury.

Keywords: ART; Creatinine clearance; HIV; Renal dysfunction; Tenofovir disoproxil fumarate.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

References

    1. World Health Organisation (WHO) Global update on HIV treatment 2013: results, impact and opportunities. Geneva: WHO; 2013. p. 2013.
    1. Ghana AIDS Commisssion (GAC). Ghana’s progress report on the United Nations General Assembly Special Session (UNGASS) declaration of commitment on HIV and AIDS Geneva, Switzerland: GAC; 2013.
    1. Eluwa GI, Badru T, Agu KA, Akpoigbe KJ, Chabikuli O, Hamelmann C. Adverse drug reactions to antiretroviral therapy (ARVs): incidence, type and risk factors in Nigeria. BMC Clin Pharmacol. 2012;12:7. doi: 10.1186/1472-6904-12-7. - DOI - PMC - PubMed
    1. Estrella M, Moosa M, Nachega J. Risk and benefits of tenofovir in the context of kidney dysfunction in sub-Sarahan Africa. CID. 2014;58(10):1481–1483. doi: 10.1093/cid/ciu123. - DOI - PMC - PubMed
    1. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292:191–201. doi: 10.1001/jama.292.2.191. - DOI - PubMed

MeSH terms